Posted by Michael Wonder on 01 Feb 2021
Biogen announces FDA approval of Plegridy (peginterferon beta-1a) intramuscular administration for multiple sclerosis
1 February 2021 - Intramuscular injection Plegridy (peginterferon beta-1a) is now approved in the U.S. and the European Union, offering individuals with relapsing multiple sclerosis a treatment option with significantly reduced injection site reactions.
Biogen today announced that the U.S. FDA has approved a new intramuscular injection route of administration for Plegridy (peginterferon beta-1a) for the treatment of relapsing forms of multiple sclerosis.
